Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Using Circulating Tumor DNA-Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer

JCO Precision Oncology report on ctDNA-based MRD for postoperative monitoring in early-stage uterine cancer, overlapping investigators with the Recio 2024 Signatera stage I series.

JCO Precis OncolPubMed 40991886DOI 10.1200/PO-25-00286